“A Phase I Double Blind, Placebo-Controlled, Randomized Study Of The Safety And Immunogenicity Of An Adjuvanted Hiv-1 Gag-Pol-Nef Fusion Protein And Adenovirus 35 Gag-Rt-Int-Nef Vaccine In Healthy Hiv-Uninfected African Adults”. Plos One 10. Plos One: e0125954. http://www.ncbi.nlm.nih.gov/pubmed/25961283.
. 2015. “Assessment Of Viral Inhibition Activity In Low Seroprevalent Adenovirus-35 Vectored Hiv Vaccines +/- Adjuvanted Protein Or Electroporated Dna”. In Hiv Research For Prevention 2014: Aids Vaccine, Microbicide And Arv-Based Prevention Science (Hivr4P). Hiv Research For Prevention 2014: Aids Vaccine, Microbicide And Arv-Based Prevention Science (Hivr4P). Cape Town, SA. http://hivr4p.org/.
. 2014. “A Phase 2 Study To Evaluate The Safety And Immunogenicity Of A Recombinant Hiv Type 1 Vaccine Based On Adeno-Associated Virus”. Aids Res Hum Retroviruses 26. Aids Res Hum Retroviruses: 933-942. http://www.ncbi.nlm.nih.gov/pubmed/20666584.
. 2010. . 2010.
. 2010.
“Lessons From Iavi-006, A Phase I Clinical Trial To Evaluate The Safety And Immunogenicity Of The Pthr.hiva Dna And Mva.hiva Vaccines In A Prime-Boost Strategy To Induce Hiv-1 Specific T-Cell Responses In Healthy Volunteers.”. Vaccine 26 (51). Vaccine: 6671-7. doi:10.1016/j.vaccine.2008.09.016.
. 2008. “Induction Of Multifunctional Human Immunodeficiency Virus Type 1 (Hiv-1)-Specific T Cells Capable Of Proliferation In Healthy Subjects By Using A Prime-Boost Regimen Of Dna-And Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes”. J Virol 80. J Virol: 4717-4728. http://www.ncbi.nlm.nih.gov/pubmed/16641265.
. 2006. “Phase 2A Dose And Route Study Of A Dna Prime Mva Boost Vaccine Candidate”. In Aids Vaccine 2005 International Conference. Aids Vaccine 2005 International Conference. Montreal, Quebec, Canada.
. 2005.